Screener
Septerna, Inc. SEPN Q2 2026 earnings
Reported August 10, 2026 · After market close
Revenue$26.7MBeat by $7.5M
EPS-$0.29Beat by $0.14
Revenue estimate$19.2M
EPS estimate-$0.43
“We are advancing our Phase 1 study of SEP-479 and are very pleased with the observed clinical half-life, which is at the longer end of our preclinical estimates. This finding reinforces our confidence in the potential of SEP-479 as a differentiated, once-daily oral treatment for hypoparathyroidism, and we look forward to presenting SAD/MAD data in the first quarter of 2027. We are also advancing our broader portfolio by evaluating the next phase of development for SEP-631 in mast cell-driven diseases and progressing our TSHR program toward development candidate selection.”
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$20.8M
EPS estimate-$0.42
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Septerna, Inc. report Q2 2026 earnings?
- Septerna, Inc. (SEPN) reported Q2 2026 earnings on August 10, 2026 after market close.
- What were Septerna, Inc.'s Q2 2026 revenue and EPS?
- Septerna, Inc. reported revenue of $26.7M and eps of $-0.29 for Q2 2026.
- Did Septerna, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $19.2M by $7.5M. EPS beat the consensus estimate of $-0.43 by $0.14.
- How did Septerna, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 22375.6% from $119.0K a year earlier and eps grew 48.2% from $-0.56.
- Where can I find Septerna, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-342328) and the 10-Q periodic report (0001193125-26-342353) directly on SEC EDGAR. The filing index links above go to sec.gov.
